There are 2867 resources available
1371P - Assessment of whether time to docetaxel impacts outcome when given in metastatic hormone-sensitive prostate cancer (MHSPC) setting
Presenter: Saby George
Session: Poster session 10
1372P - Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castration-resistant prostate cancer in the VISION trial
Presenter: Andrew Armstrong
Session: Poster session 10
1373P - SPOP mutations (mtSPOP) are a treatment-selection biomarker in patients (pts) with de novo metastatic castration-sensitive prostate cancer (dn-mCSPC)
Presenter: Umang Swami
Session: Poster session 10
1374P - Radiographic progression-free survival correlation with time-to-event endpoints: A post hoc analysis of the VISION trial
Presenter: Michael Morris
Session: Poster session 10
1375P - Intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10
1376P - Association of dynamic change in patient-reported pain with survival in metastatic castrate sensitive prostate cancer: Exploratory analysis of LATITUDE study
Presenter: Soumyajit Roy
Session: Poster session 10
1377P - Transcriptomic based indicators of potential therapeutic response to targeted therapy among 50,000 men with localized prostate cancer
Presenter: Edward Schaeffer
Session: Poster session 10
1378P - Biopsy-based basal-luminal subtyping classifier in high-risk prostate cancer: Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 randomized phase III trials
Presenter: Paul Nguyen
Session: Poster session 10
1379P - A phase Ib study of a single priming dose of 177Lu-PSMA-617 coupled with pembrolizumab in metastatic castration resistant prostate cancer (mCRPC)
Presenter: Rahul Aggarwal
Session: Poster session 10